How to assess additions to finasteride or minoxidil, including microneedling, medication switches and experimental-product claims.
An addition to a hair-loss routine needs evidence of benefit beyond the treatment already being used. A plausible mechanism or a dramatic before-and-after photograph is not enough. Check what was actually compared, whether the study matches the proposed combination, and whether another medicine or procedure would add a meaningful burden or risk.
Evidence checked September 20, 2026. This is a guide to evaluating a proposed addition with a clinician, not a ranked shopping list or self-treatment schedule.
For someone already using treatments A and B, a trial of A plus a new treatment C against A alone leaves an important question unanswered: does C add benefit to A plus B? Trials of C alone, laboratory effects and reports from people using several products answer different questions again.
The oral-finasteride and topical-minoxidil comparison reviews direct evidence for that combination. Its results do not automatically extend to oral minoxidil, different topical mixtures or a six-agent regimen.
Before considering another intervention, describe the problem: continuing loss, unwanted effects, difficulty using the product, or a wish for more regrowth despite stable hair. These are different reasons for review. A lack of further visible improvement does not, by itself, identify a missing drug.
The Dhurat 2013 pilot randomized 100 men to topical minoxidil with weekly microneedling or minoxidil alone for 12 weeks. Ninety-four completed follow-up, with all six losses from the minoxidil-only group. Hair-count and photographic outcomes favored the procedure group.
The men were aged 20–35 with specified mild-to-moderate patterns of loss; recent finasteride or other antiandrogen use was excluded. This was therefore not a trial of adding microneedling to ongoing finasteride plus minoxidil. Participants did not receive a sham procedure, follow-up was short, and different needle depths or schedules were not compared.
The study used mild erythema as its procedural endpoint and withheld minoxidil on the procedure day until 24 hours afterward. It does not support mandatory bleeding, immediate drug application or a universal home-needling schedule. For a proposed clinical plan, use our microneedling assessment questions.
Replacing finasteride with dutasteride changes an existing treatment; it is not evidence that adding both is better. A comparative drug trial cannot establish the best transition, guarantee that prior tolerance carries over, or show what an additional drug contributes to a larger stack.
Our finasteride-to-dutasteride review separates comparative evidence from switching questions. Bring the exact current regimen, reason for considering a change and any adverse effects to the prescriber. Do not infer a transition from a stronger laboratory effect alone.
Similarly, changing the route of finasteride requires formulation-specific evidence. The FDA warning on compounded topical finasteride addresses systemic effects and unintended transfer to others. Applying a medicine to the scalp does not establish that exposure stays there.
A 2026 human metabolism study of RU58841 detected the compound in blood samples after one topical application in six healthy men. The study investigated exposure, metabolism and antidoping markers. It did not test hair regrowth, repeated-use safety or an add-on regimen.
That directly limits the claim that RU58841 acts only locally. Conversely, detecting exposure does not quantify a particular long-term adverse-effect risk. Neither conclusion can be replaced by a vendor testimonial.
Pyrilutamide has separate clinical studies and sponsor announcements. Those results need their own population, formulation, comparator and date; they cannot make it an interchangeable RU58841 substitute. See the dated pyrilutamide trial review. A product marketed for research or cosmetic use must not be treated as an established human treatment merely because a related ingredient appears in a trial.
The previous version of this article referred to a small 2018 tadalafil hair trial without an identifiable citation. This update could not verify that claim, and it should not guide treatment.
The Cialis prescribing information covers erectile dysfunction and benign prostatic hyperplasia. It warns that tadalafil can augment blood-pressure lowering with other medicines and contraindicates use with organic nitrates. Vasodilation is not evidence of clinically useful hair regrowth, and adding another vasodilator is not an established remedy for oral minoxidil's cardiovascular effects. Have the prescriber or pharmacist assess the actual medicines together.
Before accepting a recommendation, record:
For a hypothetical clinic proposal to add a procedure, ask for the specific study and compare its control group with your current treatment. If they differ, record the uncertainty instead of calculating a promised extra percentage of regrowth. Our human-evidence guide explains how to check those details.
The useful next step is a justified, product-specific discussion. Adding more mechanisms to a list does not establish that the complete regimen has been tested.
Powered by BTST